

1. A substantially pure PAMP nucleic acid molecule comprising a nucleic acid sequence encoding substantially a PAMP polypeptide.

3. The substantially pure PAMP nucleic acid molecule of claim 2, comprising the nucleotide sequence shown as SEQ ID NO:1.

5. A substantially pure PAMP nucleic acid probe, comprising at least 10 contiguous nucleotides of SEQ ID NO:1, said contiguous nucleotides including at least one nucleotide of the nucleotide sequence shown as position 1 to position 3221 of SEQ ID NO:1, provided said probe does not have the nucleotide sequence of AA363808, AW959484, BE165930, nucleotides 1 to 614 of BE893201, or nucleotides 1 to 1530 of AK026780.

6. The substantially pure PAMP nucleic acid probe of claim 5, comprising at least 15 contiguous nucleotides of SEQ ID NO:1.

7. The substantially pure PAMP nucleic acid probe of claim 6, which is 15 to 18 nucleotides in length.

8. The substantially pure PAMP nucleic acid probe of claims 4, 5, 6 or 7, further comprising a detectable label.

9. A substantially pure PAMP polypeptide, comprising substantially the amino acid sequence shown as SEQ ID NO:2.

10. The substantially pure PAMP polypeptide of claim 9, comprising the amino acid sequence shown as SEQ ID NO:2.

11. A substantially pure PAMP polypeptide fragment, comprising at least eight contiguous amino acids of residues 1 to 1074 of SEQ ID NO:2.

12. The substantially pure PAMP polypeptide fragment of claim 11, comprising at least ten contiguous amino acids of residues 1 to 1074 of SEQ ID NO:2.

000001-550000

13. A method of diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual, comprising:

(a) obtaining a sample from said individual;

5 (b) measuring a test expression level of PAMP RNA by hybridization with a PAMP nucleic acid probe comprising at least 10 contiguous nucleotides of SEQ ID NO:1, said contiguous nucleotides including at least one nucleotide of the nucleotide sequence shown as position 1
10 to position 3221 of SEQ ID NO:1 in said sample; and

(c) comparing said test expression level of PAMP RNA to a control expression level of PAMP RNA, wherein a test expression level 2-fold or more greater than said control expression level indicates the
15 presence of a prostate neoplastic condition.

14. The method of claim 13, wherein said sample comprises a prostate cell.

15. The method of claim 13, wherein said sample comprises prostate tissue.

20 16. The method of claim 13, wherein said control expression level is determined using a normal prostate cell or an androgen-dependent cell line.

17. The method of claim 13, wherein said sample is a fluid selected from the group consisting of
25 blood, serum, urine and semen.

19. The method of claim 13, wherein said PAMP
0 nucleic acid probe is 15 to 18 nucleotides in length.

21. A method of diagnosing or predicting
15 susceptibility to a prostate neoplastic condition in an
individual, comprising:

(a) obtaining a sample from said individual;

(b) measuring a test expression level of PAMP polypeptide by contacting a cell, a cell lysate, or
20 fractionated sample thereof, from said individual with a binding agent selective for PAMP polypeptide residues 1 to 1074 of SEQ ID NO:2, and determining the amount of selective binding of said agent; and

(c) comparing said test expression level of
25 PAMP polypeptide to a control expression level of PAMP
polypeptide,

wherein a test expression level 2-fold or more greater than said control expression level indicates the presence of a prostate neoplastic condition.

22. The method of claim 21, wherein said
5 binding agent selective for said PAMP polypeptide residues 1 to 1074 of SEQ ID NO:2 comprises an antibody.

23. The method of claim 22, wherein said binding agent further comprises a detectable label.

24. A method of diagnosing metastatic prostate
10 cancer in an individual, comprising:

(a) obtaining a sample from said individual, wherein said sample is not a prostate sample;

(b) measuring a test expression level of PAMP RNA by hybridization with a PAMP nucleic acid probe
15 comprising at least 10 contiguous nucleotides of SEQ ID NO:1, said contiguous nucleotides including at least one nucleotide of the nucleotide sequence shown as position 1 to position 3221 of SEQ ID NO:1 in said sample; and

(c) comparing said test expression level of
20 PAMP RNA to a control expression level of PAMP RNA, wherein a significant test expression level as compared to said control expression level indicates the presence of metastatic prostate cancer.

25. A method of diagnosing metastatic prostate cancer in an individual, comprising:

(a) obtaining a sample from said individual, wherein said sample is not a prostate sample;

5 (b) measuring a test expression level of PAMP polypeptide by contacting a cell, a cell lysate, or fractionated sample thereof, from said individual with a binding agent selective for PAMP polypeptide residues 1 to 1074 of SEQ ID NO:2, and determining the amount of
10 selective binding of said agent;

(c) comparing said test expression level of PAMP polypeptide to a control expression level of PAMP polypeptide,

wherein a significant test expression level as
15 compared to said control expression level indicates the presence of metastatic prostate cancer.

Ad
B'